Please log in
to access more information

loading...

User name and Password not recognised

Home Page > The Company > Management

Management

PATRICE FERRAND PATRICE FERRAND
Chief Executive Officer

With more than 30 years of experience overall and close to 16 years of general management experience in the MedTech industry, Patrice Ferrand is a veteran leader of commercial-stage organizations. Before joining Biom’up, Mr. Ferrand was CEO at Unilabs France, a leading provider of diagnostics services in Europe and Latin America. Prior to that, for more than 11 years he was General Manager of France & Benelux for Mölnlycke Health Care, a major provider of single-use surgical and wound care products.

William D. Spotnitz William D. Spotnitz M.D., M.B.A.
Chief Medical Officer

Dr. Spotnitz is an international expert in the field of hemostats, sealants, and adhesives with more than 70 publications in this area of study. He has extensive experience in surgical needs assessment, device design, preclinical experimentation, clinical trials, FDA regulatory affairs, product education, and marketing to health professionals having collaborated with more than 30 different companies in these areas.

Valérie Centis Valérie Centis
Executive Vice President & Chief Scientific Officer

With a Ph.D. in Biotechnological and Chemical Engineering from Sherbrooke University and a Biomedical Science degree from the University of Montreal, Valerie Centis joined Biom'up in 2010 as a R&D and Regulatory Project Manager. As Chief Scientific Officer, she now manages FDA and EC product design in conformity with regulatory requirements, overseeing various teams and international collaborators.

Thierry Darnis Thierry Darnis
Global Vice President, Manufacturing & Engineering

Thierry Darnis, brings extensive experience in the management of major manufacturing sites for medical devices, acquired at top-tier global companies. At Medtronic and CR Bard he managed plants pursuing a successful twofold objective of increasing volumes, while optimizing costs. Before joining Biom’up, Thierry Darnis was deputy chief executive officer of Sofradim Production, a subsidiary of Medtronic plc (Dublin, Ireland / Minnesota, USA), and managed its Trevoux plant (340 employees) for more than 12 years. He has a Ph.D. in Life and Health Sciences, specialized in Biomaterials, from the University of Bordeaux II.

George Makhoul George Makhoul
CEO of Biom’up USA, Inc.

Mr. Makhoul has a track record in commercializing medical products to hospitals and surgeons combined with a strong experience of the US hemostasis market.
George Makhoul has over 16 years of sales, marketing, and business development leadership experience in both the medical device and pharmaceutical industries, specifically in hemostasis as well as over 13 years of targeted focus in Biosurgery, Orthopedics, and Biologics. He has led teams on both a large and small scale ranging from $10M - $1.8B in annual revenues.
Prior to joining Biom’up, Mr. Makhoul spent eight years at Stryker in multiple senior leadership positions. While at Stryker, Mr. Makhoul successfully led the sales and marketing functions of two separate new divisions within Stryker’s Orthobiologics business unit, including leading teams that developed products from conception to commercialization. Other organizations he has served prior to Stryker are Wyeth (now Pfizer), Genzyme, and Precision Therapeutics.
George Makhoul holds a degree in Business Management from Moravian College.

EVELYNE NGUYEN EVELYNE NGUYEN
Group CFO

Evelyne Nguyen has more than 30 years of international experience in financial and strategic roles, including 20 years in the pharmaceutical and biotech industry. Before joining Biom’up, Mrs. Nguyen held several senior positions at Bristol Myers Squibb and Laboratoire Français du Fractionnement et des Biotechnologies (LFB). At LFB, she strengthened Finance, led a number of significant acquisitions and successfully managed cross-border strategic alliances and business development projects. She also brings to Biom’up strong experience in strategic transactions and financing for companies in the Life Sciences domains.